Psychosis of Parkinson's disease: Serotonin 2A receptor inverse agonists as potential therapeutics

David M. Weiner*, Kimberly E. Vanover, Mark R. Brann, Herbert Y. Meltzer, Robert E. Davis

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

18 Scopus citations


Parkinson's disease (PD) is a movement disorder characterized by progressive degeneration of central dopaminergic systems. Current therapies designed to augment dopaminergic neurotransmission effectively treat the motoric aspects of the disease, however, with prolonged use, they produce a range of treatment-limiting side effects. Of these, neuropsychiatric abnormalities including hallucinosis and psychosis are common, disabling and refractory to most current therapies. This review describes the clinical syndrome of psychosis in PD and data regarding the efficacy and tolerability of existing antipsychotic agents, and presents the scientific rationale for the development of serotonin 2A receptor inverse agonists as potential therapeutic agents for treatment-induced psychosis of PD.

Original languageEnglish (US)
Pages (from-to)815-819
Number of pages5
JournalCurrent Opinion in Investigational Drugs
Issue number7
StatePublished - Jul 1 2003


  • Clozapine
  • Inverse agonist
  • Parkinson's disease
  • Psychosis
  • R-SAT
  • Serotonin 2A receptor

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery


Dive into the research topics of 'Psychosis of Parkinson's disease: Serotonin 2A receptor inverse agonists as potential therapeutics'. Together they form a unique fingerprint.

Cite this